Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Has Another Shot Remaining With Orteronel In Prostate Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III ELM-PC 5 study of orteronel in post-chemo metastatic castration-resistant prostate cancer is unblinded after drug fails to improve overall survival. But the company is continuing a Phase III trial in an earlier line of therapy.

Advertisement

Related Content

Japan Earnings Highlights: Takeda, Astellas And Eisai
Momentum In Prostate Cancer Therapy Moves Up To First-Line CRPC
FDA Approves Zytiga In Earlier Prostate Cancer Setting

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel